Prescription pattern of aromatase inhibitors for the adjuvant endocrine therapy of breast cancer - A current survey of opinion leaders in Germany;Verschreibungsverhalten von Aromataseinhibitoren in der Adjuvanten Endokrinen Therapie des Mammakarzinoms - Eine Aktuelle Bestandsaufnahme Unter Meinungsbildnern in Deutschland

Geburtshilfe und Frauenheilkunde

Volumn 69, Issue 11, 2009, Pages 1012-1019

  Luftner D ^a   Schelenz, C ^b   Possinger, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Onkologische Praxisgemeinschaft   (Germany)

Author keywords

Aromatase inhibitors; Early breast cancer; Endocrine therapy; Opinion leaders

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ADVISORY COMMITTEE; ARTICLE; BREAST CANCER; GERMANY; HORMONAL THERAPY; HUMAN; LEADERSHIP; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MEDICAL SPECIALIST; NATIONAL HEALTH INSURANCE; PHYSICIAN; POSTMENOPAUSE; PRESCRIPTION; PRIVATE HEALTH INSURANCE;

EID: 70450265357     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0029-1186259     Document Type: Article

References (30)

1. Datenreport des Statistischen Bundesamtes 2008 - Gesundheit und soziale Sicherung. Kapitel 9; 245
2. Janni W. Rack B. Sommer H. Juckstock J. Genss E. Gerber B. Friese K. Current controversis in the adjuvant systemic treatment of breast cancer Aktuelle kontroversen in der adjuvanten systemischen therapie des mammakarzinoms Geburtshilfe und Frauenheilkunde 2007 67 2 142-147 DOI 10.1055/s-2007-964936 2 Janni W, Rack B, Sommer H et al. Aktuelle Kontroversen in der adjuvanten systemischen Therapie des Mammakarzinoms. Geburtsh Frauenheilk 2007; 67: 142-147 (Pubitemid 46774542)
3. Huober J. Wagner U, Wallwiener D. Der Stellenwert von Aromatasehemmern der dritten Generation in der endokrinen Therapie des Mammakarzinoms - Zeit zum Umdenken? Geburtsh Frauenheilk 2002; 62: 15-21
4. Altundag K. Ibrahimb N.K. Aromatase inhibitors in breast cancer: An overview Oncologist 2006 11 6 553-562 http://theoncologist.alphamedpress.org/ cgi/reprint/11/6/553 DOI 10.1634/theoncologist.11-6-553 4 AltundagK Ibrahim NK. Aromatase inhibitors in breast cancer: an overview. Oncologist 2006; 11:553-562 (Pubitemid 43967611)
5. Carlini P. Bria E. Giannarelli D. Ferretti G. Felici A. Papaldo P. Fabi A. Nistico C. Di Cosimo S. Ruggeri E.M. Milella M. Mottolese M. Terzoli E. Cognetti F. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: A pooled analysis of the randomized trials Cancer 2005 104 7 1335-1342 DOI 10.1002/cncr.21339 5 Carlini P, Bria E, Giannarelli D et al. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 2005; 104: 1335-1342 (Pubitemid 41356147)
6. Ligibel J.A. Winer E.P. Aromatase inhibitors as adjuvant therapy for postmenopausal women: A therapeutic advance but many unresolved questions Breast Cancer Research 2005 7 6 255-257 DOI 10.1186/bcr1347 6 Ligibel JA, Winer EP. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Res 2005; 7: 255-257 (Pubitemid 41830163)
7. Nordman IC, Spillane AJ, Hamilton AL The aromatase inhibitors in early breast cancer: who, when, and why? Med J Aust 2005; 183: 24-27
8. Mouridsen HT, Robert NJ. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. MedGenMed 2005; 7: 20
9. Jonat W, Mundhenke C. The FACE trial: letrozole or anastrozole as initial adjuvant therapy? Cancer Invest 2007; 25:14-18
10. Coates A.S. Keshaviah A. Thurlimann B. Mouridsen H. Mauriac L. Forbes J.F. Paridaens R. Castiglione-Gertsch M. Gelber R.D. Colleoni M. Lang I. Del Mastro L. Smith I. Chirgwin J. Nogaret J.-M. Pienkowski T. Wardley A. Jakobsen E.H. Price K.N. Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98 Journal of Clinical Oncology 2007 25 5 486-492 http://jco.ascopubs.org/cgi/reprint/25/5/486 DOI 10.1200/JCO.2006.08.8617 10 Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492 (Pubitemid 350002953)
11. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 2005 365 9453 60-62 DOI 10.1016/S0140-6736(04)17666-6, PII S0140673604176666 11 Howell A, CuzickJ, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62 (Pubitemid 40082147)
12. Coombes R.C. Hall E. Gibson L.J. Paridaens R. Jassem J. Delozier T. Jones S.E. Alvarez I. Bertelli G. Ortmann O. Coates A.S. Bajetta E. Dodwell D. Coleman R.E. Fallowfield L.J. Mickiewicz E. Andersen J. Lonning P.E. Cocconi G. Stewart A. Stuart N. Snowdon C.F. Carpentieri M. Massimini G. Bliss J.M. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer New England Journal of Medicine 2004 350 11 1081-1092 DOI 10.1056/NEJMoa040331 12 Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350; 1081-1092 (Pubitemid 38298988)
13. Jonat W. Gnant M. Boccardo F. Kaufmann M. Rubagotti A. Zuna I. Greenwood M. Jakesz R. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis Lancet Oncology 2006 7 12 991-996 DOI 10.1016/S1470-2045(06)70948- 2, PII S1470204506709482 13 Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006; 7: 991-996 (Pubitemid 44804137)
14. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271
15. Jakesz R, Samonigg H, Greil R et al. Extended adjuvant treatment with anastrozole: Results frrom the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol, ASCO Annual Meeting Proceedings 2005; 23 (16S): 527
16. Mamounas EP. NSABP breast cancer clinical trials: recent results and future directions. Clin Med Res 2003; 1: 309-326
17. Jahanzeb M. Reducing the Risk for Breast Cancer Recurrence After Completion of Tamoxifen Treatment in Postmenopausal Women Clinical Therapeutics 2007 29 8 1535-1547 DOI 10.1016/j.clinthera.2007.08.013, PII S0149291807002482 17 Jahanzeb M. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Clin Ther 2007; 29: 1535-1547 (Pubitemid 47494547)
18. AGO. Leitlinie Gynäkologische Onkologie. Kommission Mamma. Arbeitsgemeinschaft Gynäkologische Onkologie 2009; http://www.ago-online. org/index.php?site=mamma-guide&lang=de
19. Goldhirsch A, Ingle JN, Gelber RD et al., Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009; 20: 1319-1329
20. Gnant M, Lang A, Marth C et al. Konsensus-Empfehlung der ABCSG. Newsletter der Austrian Breast & Colorectal Cancer Study Group - ABCSG 2005; http://www.abcsg.at/abcsg/pdf/sa.pdf
21. Winer E.P. Hudis C. Burstein H.J. Wolff A.C. Pritchard K.I. Ingle J.N. Chlebowski R.T. Gelber R. Edge S.B. Gralow J. Cobleigh M.A. Mamounas E.P. Goldstein L.J. Whelan T.J. Powles T.J. Bryant J. Perkins C. Perotti J. Braun S. Langer A.S. Browman G.P. Somerfield M.R. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004 Journal of Clinical Oncology 2005 23 3 619-629 DOI 10.1200/JCO.2005.09.121 21 Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-629 (Pubitemid 46224240)
22. Baum M. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: Where are we now? European Journal of Cancer 2005 41 12 1667-1677 DOI 10.1016/j.ejca.2005.05.006, PII S0959804905004417 22 Baum M. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now? Eur J Cancer 2005; 41:1667-1677 (Pubitemid 41132628)
23. Howell A, Buzdar A. Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol 2005; 93: 237-247
24. Luftner D. Henschke P. Pollmann D. Schildhauer S. Possinger K. Prescription pattern of aromatase inhibitors in the adjuvant setting in Germany - Final results of a survey among German breast cancer specialists Onkologie 2005 28 12 639-644 DOI 10.1159/000089339 24 Luftner D, Henschke P, Pollmann D et al. Prescription pattern of aromatase inhibitors in the adjuvant setting in Germany - final results of a survey among german breast cancer specialists. Ontologie 2005; 28: 639-644 (Pubitemid 41759066)
25. Dowsett M. Cuzick J. Wale C. Howell T. Houghton J. Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study Journal of Clinical Oncology 2005 23 30 7512-7517 DOI 10.1200/JCO.2005.01.4829 25 Dowsett M, CuzickJ, Wale C et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005; 23: 7512-7517 (Pubitemid 46291814)
26. Goss P.E. Ingle J.N. Martino S. Robert N.J. Muss H.B. Piccart M.J. Castiglione M. Tu D. Shepherd L.E. Pritchard K.I. Livingston R.B. Davidson N.E. Norton L. Perez E.A. Abrams J.S. Cameron D.A. Palmer M.J. Pater J.L. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17 Journal of Clinical Oncology 2007 25 15 2006-2011 DOI 10.1200/JCO.2006.09.4482 26 Goss PE, Ingle JN, Martino S et al., National Cancer Institute of Canada Clinical Trials Group MA.17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor. J Clin Oncol 2007; 25:2006-2011 (Pubitemid 46972784)
27. Punglia RS, Kuntz KM, Winer EP et al The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer 2006; 106:2576-2582
28. Chen S, Masri S, Wang X et al. What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol 2006; 102:232-240
29. Nicholson RI, Hutcheson IR, Hiscox SE et al. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure antioestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer 2005; 12 (Suppl. 1):S29-S36
30. Rody A, Kaufmann M. Adjuvante Therapie des Mammakarzinoms - Bericht über die 10. Internationale Expertenkonsensuskonferenz St. Gallen 2007: "Care Despite Controversies". Geburtsh Frauenheilk 2007; 67: 467